Chinese Neurosurgical Journal Report Identifies FAM111B as Key Molecular Driver of Glioma Progression
Study shows FAM111B overexpression enhances glioma malignancy via PI3K/AKT pathway, suggesting a novel treatment target
BEIJING, CHINA, May 29, 2025 / EINPresswire.com / -- Gliomas are among the deadliest brain tumors, with limited treatment options and poor survival rates. Scientists from China identified FAM111B, a DNA-repair-associated protein, as a key driver of glioma progression. The study shows that FAM111B overexpression enhances tumor growth and aggressiveness by activating the PI3K/AKT pathway. This is the first research to link FAM111B to gliomas, offering a promising new biomarker and therapeutic target for this intractable disease.
Gliomas are the most prevalent and aggressive form of primary brain tumors in adults, with dismal survival rates despite surgery, radiation, and chemotherapy. Scientists continue to search for molecular drivers that could serve as new therapeutic targets. Now, researchers led by Dr. Quan Du from Zhejiang Chinese Medical University and Westlake University in China have identified a promising candidate: a protein known as FAM111B.
'Our findings revealed that FAM111B affected glioma malignancy by modulating the PI3K/AKT pathway,' highlights lead researcher Dr. Du. 'This presents a new potential avenue for therapeutic intervention in the treatment of glioma.'
The study, published on May 19 2025, in the Chinese Neurosurgical Journal, is the first to examine the role of FAM111B in gliomas. Prior research had linked FAM111B to cell cycle regulation, DNA repair, and fibrosis-related diseases. However, its function in brain cancer was previously unknown.
Using genomic databases including The Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA), the research team found that FAM111B expression is significantly elevated in glioma tissues compared to healthy brain tissue. Moreover, higher expression levels correlated with older patient age, more advanced tumor grade, and poorer clinical outcomes—including reduced overall survival and disease-free survival. The authors confirmed these findings experimentally. Glioma cell lines and tumor samples showed significantly higher levels of FAM111B protein compared to normal tissues. When FAM111B was overexpressed in glioma cells, their proliferation, invasion, and migration dramatically increased. Conversely, knocking down FAM111B suppressed these malignant traits.
Further, in vivo experiments using mice confirmed FAM111B's role in promoting tumor growth. Mice injected with glioma cells overexpressing FAM111B developed significantly larger and heavier tumors than controls.
To uncover the molecular mechanism behind these effects, the team conducted pathway enrichment analysis. Results pointed strongly to the PI3K/AKT signaling cascade—a pathway long associated with tumor growth and resistance to therapy. Further tests showed that FAM111B overexpression increased phosphorylation of PI3K and AKT, while silencing the protein had the opposite effect.
'FAM111B regulates glioma cell malignant features via the PI3K/AKT pathway,' the Dr. Du wrote. 'These results support the hypothesis that FAM111B influences the malignant features of glioma cells primarily through the PI3K/AKT pathway.'Treatment with a PI3K inhibitor reversed the aggressive behavior caused by FAM111B overexpression, strongly suggesting a direct regulatory role. This not only strengthens the case for FAM111B as a key driver of glioma but also highlights it as a promising therapeutic target. The study's strength lies in its comprehensive approach, combining bioinformatics, cell culture, animal modeling, and molecular assays. However, the authors acknowledge the study's limitations, particularly the small patient sample size and the need for broader validation across multiple research centers.
Nonetheless, the implications are significant. Identifying FAM111B as an independent prognostic marker and a key modulator of a known cancer pathway adds a valuable tool to the glioma research arsenal.
While therapies targeting the PI3K/AKT pathway already exist, this research may pave the way for more precise, FAM111B-guided interventions. 'FAM111B has emerged not only as a critical biomarker for the development of glioma,' Dr Du concludes, 'but also as a promising novel target for therapeutic intervention.'
As researchers work to solve the complex puzzle of brain cancer, FAM111B may soon take center stage.
***
Reference
Title of original paper: The role of FAM111B in the malignant progression and molecular regulation of human glioma through the PI3K/Akt pathway
Journal: Chinese Neurosurgical Journal
DOI: https://doi.org/10.1186/s41016-025-00395-6
Yi Lu
Chinese Neurosurgical Journal
+86 10 5997 8478
[email protected]
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
a day ago
- Associated Press
Bullpen Launches Emerging Fund to Champion the Next Generation of Life Sciences Innovators
New investment initiative fuels high-potential startups across biotools, medtech, digital health, and therapeutics. 'BIO Week is our opportunity to strip away the noise and create a space where life science leaders can connect authentically, share candid insights, and forge the partnerships.'— Christiaan Engstrom, CEO of Bullpen. BOSTON, MA, UNITED STATES, June 4, 2025 / / -- Bullpen, a trusted community of life sciences dealmakers, today announced the launch of its Bullpen Emerging Fund, a bold initiative designed to back mission-driven startups that are redefining the future of health. Through capital investment, deep mentorship, and access to a close-knit network of expert operators and investors, the fund aims to turn today's early-stage breakthroughs into tomorrow's clinical realities. The Emerging Fund, available to accredited investors, invests in standout companies selected for Bullpen's On-Deck class—founders chosen not only for their science but for their grit, vision, and purpose. The 2025 cohort includes: - Chandima Bandaranayaka, CEO: Precision Quantomics, accelerating drug discovery and personalized pharmacotherapy through high-resolution molecular profiling. - David Mead, CEO: Terra Bioforge, harnessing synthetic biology to streamline biological production and accelerate therapeutic development. - Doug Cohen, CEO: IR Medtek, developing real-time, noninvasive cancer detection technologies that improve early diagnosis and patient outcomes. - Harsha Rajasimha, CEO: Jeeva Clinical Trials, delivering decentralized trial software that enhances patient access, retention, and diversity in clinical research. - Linda Tempelman, CEO: Persista Bio, advancing cell therapy solutions for chronic diseases, including a novel approach to treating Type 1 diabetes. Each of these founders will pitch during Bullpen's 'Money Ball' sessions, June 16–18 at BIO International, to an audience of mission-aligned investors and partners. More than a moment on stage, these pitches represent the culmination of rigorous preparation and the start of a meaningful growth journey. 'Bullpen was built on a simple idea: if you bring the right people together in the right way, the outcomes take care of themselves. BIO Week is our opportunity to strip away the noise and create a space where life science leaders can connect authentically, share candid insights, and forge the partnerships that will move this industry forward,' said Christiaan Engstrom, CEO of Bullpen. Further information on the Bullpen Emerging Fund may be obtained from Ray Jordan, managing director, Putnam Insights LLC, and initial investor in the fund through Elmstead Partners LLC. Jordan may be reached at [email protected]. Expert Coaching to Catalyze Success Behind each founder is a seasoned mentor: - Michael Hill, Global Head of Science Innovations, MedTech Head Coach, with a legacy of scaling clinical tools from bench to bedside. - Stella Vnook, CEO of Likarda and Therapies Head Coach, a biotech operator with deep experience in moving science-backed products through commercial launch. - John Bonham-Carter, BioTools Head Coach and angel investor, guiding early-stage science into successful enterprise with strategic insight and operational depth. Throughout the week, Bullpen will host engaging programming across Boston innovation hubs like Portal Innovations, SmartLabs, and EPAM Continuum. Key agenda highlights include: Agenda Highlights Include: - Investor interviews with leaders from Novo Nordisk, Cincytech, DigitalDx, Mayo Clinic, Riverside Partners, and others, with open Q&A in the Press Room following each session. - Thematic forums exploring pivotal industry issues such as: - AI in Healthcare: Exploring how artificial intelligence is reshaping patient care and discovery. - Patient Access: Breaking down barriers to get therapies to those who need them most. - Tech Transfer: Bridging academic science and commercial application. - Rare Disease: Elevating patient voices and rare innovation journeys. - Global Forums: Perspectives from Japan, Korea, Canada, and Australia spotlighting international innovation. - Women in VC and venture insights sessions, giving voice to underrepresented perspectives in capital formation and funding trends. As BIO Week wraps, Bullpen leaves behind more than a schedule, it strengthens a movement. One that champions science, centers people, and dares to do things differently. With the Emerging Fund as its catalyst, Bullpen is helping the next generation of health innovators go further, faster. About Bullpen: Founded on the mantra Find Someone to Help. Repeat., Bullpen is a volunteer-led, member-driven network designed to foster meaningful connections and accelerate innovation in life sciences. With no booths or sales pitches, Bullpen cultivates a space where authentic conversation drives real outcomes. Its members include public and private company leaders, VCs, strategics, accelerators, and non-profit executives dedicated to building the future of health. Media Inquiries: Madelyn De Los Santos Putnam Insights email us here Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Associated Press
a day ago
- Associated Press
Young Philanthropist Jahkil Naeem Jackson Releases His Third Book: 'Built Different'
Two-Time Best Selling Author, Jahkil Naeem Jackson, Releases His Third Empowering Book, 'Built Different' — A Must-Read Blueprint for Today's Youth 'I want readers to know that being different is a strength — your path won't look like everyone else's, and that's exactly the point'— Jahkil Jackson CHICAGO, CA, UNITED STATES, June 4, 2025 / / -- Following the success of his previous books 'I Am' and 'Don't Wait to Be Great', 17-year-old CNN Hero, student-athlete, motivational speaker, and non-profit founder Jahkil Naeem Jackson returns with his most powerful work yet — 'Built Different.' At just 17, Jahkil has already become a nationally recognized change-maker, and his latest book delivers raw honesty, inspiration, and practical advice for teenagers navigating the pressures of growing up in today's fast-paced, image-driven world. 'Built Different' is more than just a book — it's a real-talk guide for teens who are striving to be their best selves while battling the pressure to be perfect. Equal parts motivational blueprint and uplifting pep talk, the book creates a safe space where young people can feel seen, heard, and empowered to lead with authenticity. Jahkil opens up about his own life experiences — balancing academics, athletics, entrepreneurship, leadership, and mental wellness — offering readers mindset tools and real-life strategies they can actually apply to their own journeys. 'I want readers to know that being different is a strength — your path won't look like everyone else's, and that's exactly the point,' says Jahkil. 'This book is about embracing who you are, even when the world tries to tell you to be something else.' With a strong focus on mental health awareness, self-leadership, and resilience, 'Built Different' speaks directly to the challenges today's teens face — from anxiety and burnout to the pressure of social media and expectations from others. Jahkil's voice is relatable, compassionate, and refreshingly authentic, making 'Built Different' a must-read for youth, parents, educators, and anyone invested in helping the next generation succeed. Jahkil's journey has already inspired thousands. As the founder of Project I Am — a nonprofit organization dedicated to supporting the homeless — he has proven that age is no barrier to impact. With 'Built Different', he continues to show that purpose, courage, and leadership can start at any age. 'Built Different' is now available online at Amazon and Barnes & Noble. Claudia Greene Mayhem Entertainment Public Relations email us here Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Associated Press
a day ago
- Associated Press
Jim Marter: I will not be silent in the face of Colorado Terror Attack and Homeland Security Failures
Jim Marter: I will not be silent in the face of Colorado Terror Attack and Homeland Security Failures 'This attack on the innocent, including a Holocaust survivor, is a stark reminder that we need to demand secure borders and immigration enforcement or we'll face more terrorism and anti-Semitism.'— Jim Marter OSWEGO, IL, UNITED STATES, June 4, 2025 / / -- Today, Republican congressional candidate Jim Marter urged an end to the silence regarding the heinous terror attack in Boulder, Colorado over the weekend where eight individuals were injured during a peaceful pro-Israel rally. So far, Marter's opponent has made released no similar, official statement. The facts are, the suspect, Mohamed Soliman, reportedly used incendiary devices and a makeshift flamethrower in an act authorities are investigating as domestic terrorism, allegedly motivated by radical Islamic extremism and anti-Semitism. Among the victims were four men and four women. Two suffered severe burns and had to be airlifted to a burn unit. One of the victims is an 88-year-old Holocaust survivor, and another is a professor at the University of Colorado. 'This brutal attack on innocent Americans, including a Holocaust survivor, is a stark reminder of the threats posed by radical ideologies,' said Marter. 'It's deeply concerning that anyone could remain silent in the face of this act of terror and anti-Semitism.' Soliman, overstayed his visa and was therefore residing illegally here in the United States. Thankfully, he was apprehended at the scene and is currently facing multiple charges. 'Our elected officials have a duty to speak out against such heinous acts and to ensure the safety and security of all Americans,' Marter continued. 'Silence can put Americans at risk and embolden would-be terrorists. If we fail to stand strong in the face of terrorism and lawlessness, we'll see more of this,' said Marter. Jim Marter is a principled Republican for Congress in Illinois' 14th District. He is a small business owner, husband, and father, with a long record of serving the community, standing against violence and discrimination, and fighting for individual freedoms, secure borders, and accountable government. To learn more about Marter for Congress, visit Campaign HQ Marter for Congress +1 815-585-8006 email us here Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
